Prolactin gene expression in primary central nervous system tumors

Journal of Negative Results in Biomedicine

Miriam da Costa Oliveira²  Nelson Pires Ferreira²  Marlise Di Domenico¹  Geraldine Trott¹  Maria Beatriz Kohek³  Júlia Fernanda Semmelmann Pereira-Lima²  Graziella Alebrant Mendes³ 

[1] Biomedicine Student, UFCSPA, Porto Alegre, Brazil;Center of Neuroendocrinology, Complexo Hospitalar Santa Casa, Porto Alegre/RS, CEP, 90020-090, Brazil;Postgraduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil

关键词: gene expression;    quantitative real-time PCR;    immunohistochemistry;    CNS tumors;    Prolactin;   

Others  :  812557
DOI  :  10.1186/1477-5751-12-4

 received in 2012-03-19, accepted in 2013-01-03,  发布年份 2013

【 摘 要 】

Background

Prolactin (PRL) is a hormone synthesized in both the pituitary gland and extrapituitary sites. It has been associated with the occurrence of neoplasms and, more recently, with central nervous system (CNS) neoplasms. The aim of this study was to evaluate prolactin expression in primary central nervous system tumors through quantitative real-time PCR and immunohistochemistry (IH).

Results

Patient mean age was 49.1 years (SD 15.43), and females accounted for 70% of the sample. The most frequent subtype of histological tumor was meningioma (61.5%), followed by glioblastoma (22.9%). Twenty cases (28.6%) showed prolactin expression by immunohistochemistry, most of them females (18 cases, 90%). Quantitative real-time PCR did not show any prolactin expression.

Conclusions

Despite the presence of prolactin expression by IH, the lack of its expression by quantitative real-time PCR indicates that its presence in primary tumors in CNS is not a reflex of local production.

【 授权许可】

   
2013 Alebrant Mendes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ben-Jonathan N, LaPensee CR, LaPensee EW: What can we learn from rodents about prolactin in humans? Endocr Rev 2008, 29:1-31.
• [2]Ben-Jonathan N, Mershon J, Allen D, Steinmetz R: Extrapituitary prolactin: distribuition, regulation, functions and clinical aspects. Endocr Rev 1996, 17:639-669.
• [3]Jabbour HN, Gubbay O, Chritchley H: Prolactin action and signalling in the human endometrium. Reprod Med Rev 2002, 10:117-132.
• [4]Freeman ME, Kanycska B, Lerant A, Nagy A: Prolactin: structure, function and regulation of secretion. Physiol Rev 2000, 80:1523-1631.
• [5]Ginsburg E, Vonderhaar BK: Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995, 55:2591-2595.
• [6]Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND: Prolactin gene- disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000, 19:1077-1084.
• [7]LaPensee EW, Ben-Jonathan N: Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer 2010, 17:91-107.
• [8]Wennbo H, Kindblom J, Isaksson OG, Tornell J: Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997, 138:4410-4415.
• [9]Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT: Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999, 140:5412-5421.
• [10]Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT: Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004, 64:4774-4782.
• [11]Bhatavdekar J, Patel D, Ghosh N, Vora H, Shah N, Karelia N, Balar D, Chikhlikar P, Dave R: Interrelationship of prolactin and its receptor in carcinoma of the colon and rectum:a preliminary report. J Surg Oncol 1994, 55:246-249.
• [12]Ciccarelli E, Razzore P, Gaia D, Todaro C, Longo A, Forni M, Ghè C, Camanni F, Muccioli G, Faccani G, Lanote MM: Hyperprolactinaemia and prolactin binding in benign intracranial tumors. J Neurosurg 2001, 45:70-74.
• [13]Leães CGS, Pereira-Filho A, Pereira-Lima JFS, Dallago CM, Batista RL, Coutinho LMB, Ferreira NP, Oliveira MC: Hyperprolactinemia and immunohistochemical expression of intracellular prolactin and prolactin receptor in primary central nervous system tumors and their relationship with cellular replication. Brain Tumor Pathol 2007, 24:41-46.
• [14]Abech DMD, Pereira-Lima JFS, Leães CGS, Meurer RT, Barbosa-Coutinho LM, Ferreira NP, Oliveira MC: Cell replication and angiogenesis in central nervous system tumors and their relationship with the expression of tissue prolactin and hyperprolactinemia. OJPathology 2012, 2:50-57.
• [15]Flowers A: Brain tumors in the older person. Cancer Control 2000, 7:523-538.
• [16]DeAngelis LM: Brain tumors. N Engl J Med 2001, 344:114-123.
• [17]Sagar SM, Israel MA: Primary and metastatic tumors of the nervous system. In Harrison’s Principle of Internal Medicine. 16th edition. Edited by Jameson JL. New York: McGraw-Hill; 2005:2452.
• [18]Girolami UD, Anthony DC, Frosch MP: The central nervous system. In Pathologic Basis of Disease. 7th edition. Edited by Cotran R, Kumor V, Robbins S. Philadelphia: WB Saunders; 2004:1243-1357.
• [19]McCowen K, Glickman J, Black P, Zervas N, Lidov H, Garber J: Gangliocitoma masquerading as a prolactinoma. Case report. J Neurosurg 1999, 91:490-495.
• [20]Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burnet NG, Coleman N: Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol 2005, 31:455-466.
• [21]Ducret T, Boudina S, Sorin B, Vacher AM, Gourdou I, Liguoro D, Guerin J, Bresson-Bepoldin L, Vacher P: Effects of prolactin on intracellular and cell proliferation in human glioma cells. Glia 2002, 38:200-214.
• [22]Jimenez-Hakim E, El-Azouzi M, Black P: The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture. J Neurooncol 1993, 16:185-190.
• [23]Fields K, Kulig E, Lloyd RV: Detection of prolactin messenger RNA in mammary and other normal and neoplasic tissues by polymerase chain reaction. Lab Invest 1993, 68:354-360.
• [24]Schachter BS, Durgerian S, Harlan RE, Pfaff DW, Shivers BD: Prolactin mRNA exists in rat hypothalamus. Endocrinology 1984, 114:1947-1949.
• [25]Emanuele NV, Jurgens JK, Halloran MM, Tentler JJ, Lawrence AM, Kelley MR: The rat prolactin gene is expressed in brain tissue: detection of normal and alternatively spliced prolactin messenger RNA. Mol Endocrinol 1992, 6:35-42.
• [26]Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, Sindelka R, Sjöback R, Sjögreen B, Strömbom L, Stahlberg A, Zoric N: The real-time polymerase chain reaction. Mol Aspects Med 2006, 27:95-125.
• [27]Ding C, Cantor CR: Quantitative analysis of nucleic acids - the last Few years of progress. J Biochem Mol Biol 2004, 37:1-10.
• [28]Bustin AS: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193.
• [29]Whitman DF, Dunbar SA: Real-time polymerase chain reaction detection methods. Recent Pat DNA Gene Seq 2008, 2:20-26.
• [30]Ramos-Vara JA: Technical aspects of immunohistochemistry. Vet Pathol 2005, 42:405-426.
• [31]van Maanen C, Wouda W, Schares G, von Blumröder D, Conraths FJ, Norton R, Williams DJ, Esteban-Redondo I, Innes EA, Mattsson JG, Björkman C, Fernández-García A, Ortega-Mora LM, Müller N, Sager H, Hemphill A: An interlaboratory comparison of immunohistochemistry and PCR methods for detection of neospora caninum in bovine foetal tissues. Vet Parasitol 2004, 126:351-364.
• [32]Pisarek H, Stępień T, Kubiak R, Borkowska E, Pawlikowski M: Expression of Somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2009, 2:1-8. BioMed Central Full Text
• [33]Wildemberg LE, Vieira Neto L, Costa DF, Nasciutti LE, Takiya CM, Alves LM, Gadelha MR: Validation of immunohistochemistry for Somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry. J Endocrinol Invest 2011, 34:573-580.
• [34]Mackay IM: Real-time PCR in the microbiology laboratory. Clin Microbiol Infec 2004, 10:190-212.
• [35]Wong ML, Medrano JF: Real-time PCR for mRNA quantification. Biotechniques 2005, 39:75-85.
• [36]Mortarino M, Franceschi A, Mancianti F, Bazzocchi C, Genchi C, Bandi C: Quantitative PCR in the diagnosis of leishmania. Parassitologia 2004, 46:163-167.
• [37]Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V: Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000, 19:4695-4705.
• [38]Schaber JD, Fang H, Xu J, Grimley PM, Rui H: Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells. Cancer Res 1998, 58:1914-1919.
• [39]Das R, Vonderhaar BK: Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene 1996, 13:1139-1145.
• [40]Acosta JJ, Muñoz RM, González L, Subtil-Rodríguez A, Dominguez-Caceres MA, García-Martínez JM, Calcabrini A, Lazaro-Trueba I, Martín-Pérez J: Src mediates prolactin-dependent proliferation of T47DandMCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 2003, 17:2268-2282.
• [41]Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev 2003, 24:1-27.
• [42]Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A: Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal 2011, 23:1794-1805.
• [43]Fresno Vara JA, Caceres MA, Silva A, Martin-Perez J: Src family kinases are required for prolactin induction of cell proliferation. Mol Biol Cell 2001, 12:2171-2183.
• [44]Walsh RJ, Slaby FJ, Posner BI: A receptor-mediated mechanism for the transport of prolactin from blood to cerebrospinal fluid. Endocrinology 1987, 120:1846-1850.
• [45]Mangurian LP, Walsh RJ, Posner BI: Prolactin enhancement of its own uptake at the choroid plexus. Endocrinology 1992, 131:698-702.
• [46]Pawlikowski M, Kunert-Radek J, Radek M: Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Endokrynol Pol 2010, 61:63-66.
• [47]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods 2001, 25:402-408.